Steven Finkelstein, MD, DABR, FACRO

Steven Finkelstein, MD, DABR, FACRO, spoke about the impact of the approval of 177Lu for patients with PSMA-positive mCRPC.

Panelists discuss how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Panelists discuss how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.

Panelists discuss how genomic testing has revolutionized patient selection for active surveillance by integrating molecular insights that transcend traditional clinical parameters, enabling more nuanced risk stratification and personalized management of intermediate-risk prostate cancer.

Panelists discuss how advanced multi-omics approaches, personalized precision medicine techniques, artificial intelligence–driven genetic interpretation tools, and emerging gene editing technologies such as CRISPR (clustered regularly interspaced short palindromic repeats) are poised to revolutionize clinical practice by enabling more targeted diagnostics, predictive risk assessments, and individualized treatment strategies across oncology, rare disease management, and chronic condition prevention.

Panelists discuss how genomic biomarker testing has revolutionized prostate cancer management by enabling a precision medicine approach that transitions from population-based treatments to individualized therapeutic strategies based on precise molecular profiling.

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.

Drs Brian Helfand and Steven Finkelstein share key takeaways and clinical pearls from the phase 2/3 EMPIRE-1 trial for prostate cancer.

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, review results from the phase 2/3 EMPIRE-1 trial examining the use of ¹⁸F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy for prostate cancer.